| Model‐based drug development RL Lalonde, KG Kowalski, MM Hutmacher, W Ewy, DJ Nichols, ... Clinical Pharmacology & Therapeutics 82 (1), 21-32, 2007 | 514 | 2007 |
| Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration TJ Walsh, MO Karlsson, T Driscoll, AG Arguedas, P Adamson, ... Antimicrobial agents and chemotherapy 48 (6), 2166-2172, 2004 | 407 | 2004 |
| Good practices in model‐informed drug discovery and development: practice, application, and documentation EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ... CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016 | 264 | 2016 |
| Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies MO Karlsson, I Lutsar, PA Milligan Antimicrobial agents and chemotherapy 53 (3), 935-944, 2009 | 253 | 2009 |
| Model‐based drug development: a rational approach to efficiently accelerate drug development PA Milligan, MJ Brown, B Marchant, SW Martin, PH Van Der Graaf, ... Clinical Pharmacology & Therapeutics 93 (6), 502-514, 2013 | 251 | 2013 |
| Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children TJ Walsh, T Driscoll, PA Milligan, ND Wood, H Schlamm, AH Groll, H Jafri, ... Antimicrobial agents and chemotherapy 54 (10), 4116-4123, 2010 | 164 | 2010 |
| Models for time‐varying covariates in population pharmacokinetic‐pharmacodynamic analysis U Wählby, AH Thomson, PA Milligan, MO Karlsson British journal of clinical pharmacology 58 (4), 367-377, 2004 | 85 | 2004 |
| Telephone follow‐up to improve glycaemic control in patients with type 2 diabetes: systematic review and meta‐analysis of controlled trials L Wu, A Forbes, P Griffiths, P Milligan, A While Diabetic Medicine 27 (11), 1217-1225, 2010 | 82 | 2010 |
| A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction PA Milligan, SF Marshall, MO Karlsson British journal of clinical pharmacology 53, 45S-52S, 2002 | 82 | 2002 |
| A pharmacokinetic‐pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether‐a‐go‐go‐related gene current inhibition data DM Jonker, LA Kenna, D Leishman, R Wallis, PA Milligan, EN Jonsson Clinical pharmacology & therapeutics 77 (6), 572-582, 2005 | 81 | 2005 |
| Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ... CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019 | 80 | 2019 |
| The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA modeling and simulation workshop E Manolis, S Rohou, R Hemmings, T Salmonson, M Karlsson, PA Milligan CPT: pharmacometrics & systems pharmacology 2 (2), 1-4, 2013 | 71 | 2013 |
| PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ... CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013 | 69 | 2013 |
| Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and … T Kerbusch, U Wählby, PA Milligan, MO Karlsson British journal of clinical pharmacology 56 (6), 639-652, 2003 | 66 | 2003 |
| PKPD modeling of predictors for adverse effects and overall survival in sunitinib‐treated patients with GIST EK Hansson, G Ma, MA Amantea, J French, PA Milligan, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 2 (12), 1-9, 2013 | 55 | 2013 |
| Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography PA Milligan Journal of Chromatography B: Biomedical Sciences and Applications 576 (1 …, 1992 | 44 | 1992 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population … T Kerbusch, PA Milligan, MO Karlsson British journal of clinical pharmacology 57 (2), 170-180, 2004 | 30 | 2004 |
| Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients L Claret, F Mercier, BE Houk, PA Milligan, R Bruno Cancer chemotherapy and pharmacology 76, 567-573, 2015 | 23 | 2015 |
| Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children TJ Walsh, TA Driscoll, AC Arietta, N Klein, J Bradley, H Jafri, H Schlamm, ... 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30, 2006 | 22 | 2006 |
